
Sarah E Wakeman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5017127/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Network Open, 2020, 3, e1920622.	2.8	505
2	Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Medicine, 2019, 16, e1002969.	3.9	230
3	Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States. JAMA Network Open, 2019, 2, e187621.	2.8	220
4	Inpatient Addiction Consultation for Hospitalized Patients Increases Post-Discharge Abstinence and Reduces Addiction Severity. Journal of General Internal Medicine, 2017, 32, 909-916.	1.3	173
5	Understanding why Patients with Substance use Disorders Leave the Hospital against Medical Advice: A Qualitative Study. Substance Abuse, 2020, 41, 519-525.	1.1	171
6	Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities. New England Journal of Medicine, 2018, 379, 1-4.	13.9	150
7	Barriers to Medications for Addiction Treatment: How Stigma Kills. Substance Use and Misuse, 2018, 53, 330-333.	0.7	148
8	Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder. JAMA Psychiatry, 2019, 76, 229.	6.0	134
9	Attitudes, Practices, and Preparedness to Care for Patients with Substance use Disorder: Results from a Survey of General Internists. Substance Abuse, 2016, 37, 635-641.	1.1	118
10	An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. Nature Medicine, 2020, 26, 819-820.	15.2	112
11	Language, Substance Use Disorders, and Policy: The Need to Reach Consensus on an "Addiction-ary― Alcoholism Treatment Quarterly, 2016, 34, 116-123.	0.5	111
12	Stop Talking †Dirty': Clinicians, Language, and Quality of Care for the Leading Cause of Preventable Death in the United States. American Journal of Medicine, 2015, 128, 8-9.	0.6	103
13	Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality. Annals of Internal Medicine, 2019, 171, 1.	2.0	86
14	Inpatient Addiction Consult Service. Medical Clinics of North America, 2018, 102, 587-601.	1.1	81
15	Internal Medicine Residents' Training in Substance Use Disorders: A Survey of the Quality of Instruction and Residents' Self-Perceived Preparedness to Diagnose and Treat Addiction. Substance Abuse, 2013, 34, 363-370.	1.1	72
16	Addressing Substance use Disorder in Primary Care: The Role, Integration, and Impact of Recovery Coaches. Substance Abuse, 2018, 39, 307-314.	1.1	71
17	Addiction Treatment Within U.S. Correctional Facilities: Bridging the Gap Between Current Practice and Evidence-Based Care. Journal of Addictive Diseases, 2015, 34, 220-225.	0.8	61
18	Barriers to Post-Acute Care for Patients on Opioid Agonist Therapy; An Example of Systematic Stigmatization of Addiction. Journal of General Internal Medicine, 2017, 32, 17-19.	1.3	58

#	Article	IF	CITATIONS
19	Medications For Addiction Treatment: Changing Language to Improve Care. Journal of Addiction Medicine, 2017, 11, 1-2.	1.4	56
20	Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: A qualitative study of a bridge clinic. Journal of Substance Abuse Treatment, 2019, 107, 1-7.	1.5	56
21	Changes in characteristics of drug overdose death trends during the COVID-19 pandemic. International Journal of Drug Policy, 2021, 98, 103392.	1.6	47
22	No End to the Crisis without an End to the Waiver. Substance Abuse, 2018, 39, 263-265.	1.1	46
23	Peer recovery coaches in general medical settings: Changes in utilization, treatment engagement, and opioid use. Journal of Substance Abuse Treatment, 2021, 122, 108248.	1.5	46
24	Using Science to Battle Stigma in Addressing the Opioid Epidemic: Opioid Agonist Therapy Saves Lives. American Journal of Medicine, 2016, 129, 455-456.	0.6	43
25	Outcomes According to Discharge Location for Persons Who Inject Drugs Receiving Outpatient Parenteral Antimicrobial Therapy. Open Forum Infectious Diseases, 2018, 5, ofy056.	0.4	42
26	Emergency Department Treatment of Opioid Addiction: An Opportunity to Lead. Academic Emergency Medicine, 2018, 25, 601-604.	0.8	41
27	Therapies Offered at Residential Addiction Treatment Programs in the United States. JAMA - Journal of the American Medical Association, 2020, 324, 804.	3.8	41
28	Effect of Integrating Substance Use Disorder Treatment into Primary Care on Inpatient and Emergency Department Utilization. Journal of General Internal Medicine, 2019, 34, 871-877.	1.3	36
29	Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery. Addiction, 2020, 115, 291-301.	1.7	36
30	Comparison of Methods for Alcohol and Drug Screening in Primary Care Clinics. JAMA Network Open, 2021, 4, e2110721.	2.8	33
31	Opioid overdose decedent characteristics during COVID-19. Annals of Medicine, 2022, 54, 1081-1088.	1.5	31
32	Predictors for 30-Day and 90-Day Hospital Readmission Among Patients With Opioid Use Disorder. Journal of Addiction Medicine, 2019, 13, 306-313.	1.4	29
33	Institutional Substance Use Disorder Intervention Improves General Internist Preparedness, Attitudes, and Clinical Practice. Journal of Addiction Medicine, 2017, 11, 308-314.	1.4	28
34	Why It's Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy. AMA Journal of Ethics, 2017, 19, 922-930.	0.4	27
35	Massachusetts Medical Students Feel Unprepared to Treat Patients with Substance Use Disorder. Journal of General Internal Medicine, 2018, 33, 249-250.	1.3	27
36	Implementing Opioid Agonist Treatment in Correctional Facilities. JAMA Internal Medicine, 2018, 178, 1153.	2.6	27

#	Article	IF	CITATIONS
37	Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence. Journal of Addiction Medicine, 2019, 13, 253-257.	1.4	27
38	Impact of Inpatient Addiction Consultation on Hospital Readmission. Journal of General Internal Medicine, 2021, 36, 2161-2163.	1.3	27
39	Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department. Western Journal of Emergency Medicine, 2020, 21, 257-263.	0.6	26
40	Medicine Resident Preparedness to Diagnose and Treat Substance use Disorders: Impact of an Enhanced Curriculum. Substance Abuse, 2015, 36, 427-433.	1.1	25
41	Removing One Barrier to Opioid Use Disorder Treatment. JAMA - Journal of the American Medical Association, 2021, 325, 1147.	3.8	25
42	Fulfilling the Mission of Academic Medicine: Training Residents in the Health Needs of Prisoners. Journal of General Internal Medicine, 2010, 25, 186-188.	1.3	24
43	Get Waivered: A Resident-Driven Campaign to Address the Opioid Overdose Crisis. Annals of Emergency Medicine, 2019, 74, 691-696.	0.3	24
44	Diagnosis and Treatment of Opioid Use Disorder in 2020. JAMA - Journal of the American Medical Association, 2020, 323, 2082.	3.8	24
45	The Inmate Exception and Reform of Correctional Health Care. American Journal of Public Health, 2017, 107, 384-385.	1.5	23
46	Managing Opioid Use Disorder During and After Acute Hospitalization: A Case-Based Review Clarifying Methadone Regulation for Acute Care Settings. The Journal of Addictive Behaviorsrapy & Rehabilitation, 2015, 04, .	0.2	23
47	HIV treatment in US prisons. HIV Therapy, 2010, 4, 505-510.	0.6	22
48	Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series. Journal of Substance Abuse Treatment, 2021, 126, 108316.	1.5	19
49	Overcoming Barriers to Treatment of Opioid Use Disorder. JAMA - Journal of the American Medical Association, 2021, 325, 1149.	3.8	19
50	The Prevalence of Unhealthy Alcohol and Drug use among Inpatients in a General Hospital. Substance Abuse, 2020, 41, 331-339.	1.1	18
51	Robustness of estimated access to opioid use disorder treatment providers in rural vs. urban areas of the United States. Drug and Alcohol Dependence, 2021, 228, 109081.	1.6	18
52	Diagnosis and Management of Infective Endocarditis in People Who Inject Drugs. Journal of the American College of Cardiology, 2022, 79, 2037-2057.	1.2	18
53	The Impact of Access to Addiction Specialist on Attitudes, Beliefs and Hospital-Based Opioid Use Disorder Related Care: A Survey of Hospitalist Physicians. Substance Abuse, 2022, 43, 143-151.	1.1	17
54	Drug dependence is not addiction—and it matters. Annals of Medicine, 2021, 53, 1989-1992.	1.5	17

#	Article	IF	CITATIONS
55	Vitamin D deficiency exacerbates UV/endorphin and opioid addiction. Science Advances, 2021, 7, .	4.7	16
56	Multidisciplinary team approach to confront the challenge of drug use–associated infective endocarditis. Journal of Thoracic and Cardiovascular Surgery, 2023, 166, 457-464.e1.	0.4	16
57	Physicians in US Prisons in the Era of Mass Incarceration. International Journal of Prisoner Health, 2010, 6, 100-106.	0.5	15
58	Practicing What We Preach — Ending Physician Health Program Bans on Opioid-Agonist Therapy. New England Journal of Medicine, 2019, 381, 796-798.	13.9	14
59	A Hospital-Wide Initiative to Redesign Substance use Disorder Care: Impact on Pharmacotherapy Initiation. Substance Abuse, 2021, 42, 767-774.	1.1	14
60	Treating Opioid Withdrawal in the Hospital: A Role for Short-Acting Opioids. Annals of Internal Medicine, 2022, 175, 283-284.	2.0	13
61	The Effectiveness of Post-Discharge Navigation Added to an Inpatient Addiction Consultation for Patients with Substance use Disorder; a Randomized Controlled Trial. Substance Abuse, 2021, 42, 646-653.	1.1	11
62	Redefining Child Protection. Obstetrics and Gynecology, 2022, 140, 167-173.	1.2	11
63	Substance Use Disorder and Telemedicine: Opportunity and Concern for the Future. Journal of General Internal Medicine, 2020, 36, 2823-2824.	1.3	10
64	Opioid Prescribing After Implementation of Single Click Access to a State Prescription Drug Monitoring Program Database in a Health System's Electronic Health Record. Pain Medicine, 2021, 22, 2218-2223.	0.9	10
65	Rapid Buprenorphine Microdosing for Opioid use Disorder in a Hospitalized Patient Receiving Very High Doses of Full Agonist Opioids for Acute Pain Management: Titration, Implementation Barriers, and Strategies to Overcomes. Substance Abuse, 2021, 42, 506-511.	1.1	10
66	Rise in Presence of Methamphetamine in Oral Fluid Toxicology Tests Among Outpatients in a Large Healthcare Setting in the Northeast. Journal of Addiction Medicine, 2021, 15, 85-87.	1.4	10
67	Case 37-2017. New England Journal of Medicine, 2017, 377, 2181-2188.	13.9	9
68	Opioid Use Disorder, Stigma, and Transplantation: A Call to Action. Annals of Internal Medicine, 2018, 169, 188.	2.0	9
69	Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder. Medical Care, 2020, 58, 919-926.	1.1	9
70	Use of promethazine, gabapentin and clonidine in combination with opioids or opioid agonist therapies among individuals attending a syringe service program. International Journal of Drug Policy, 2020, 79, 102752.	1.6	9
71	Drug- and Alcohol-Associated Deaths in U.S. Jails. Journal of Correctional Health Care, 2020, 26, 183-193.	0.2	9
72	Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid COVID-19 and Beyond. American Journal of Public Health, 2021, 111, 1013-1017.	1.5	8

#	Article	IF	CITATIONS
73	From Documenting Death to Comprehensive Care: Applying Lessons from the HIV/AIDS Epidemic to Addiction. American Journal of Medicine, 2014, 127, 465-466.	0.6	7
74	Societal Biases, Institutional Discrimination, and Trends in Opioid Use in the USA. Journal of General Internal Medicine, 2021, 36, 797-801.	1.3	7
75	Substance use disorders and avoidable mortality after prison. Lancet Psychiatry,the, 2015, 2, 369-370.	3.7	6
76	Agreement between self-reported psychoactive substance use and urine toxicology results for adults with opioid use disorder admitted to hospital. Toxicology Communications, 2019, 3, 94-101.	0.3	6
77	Asking How Our Patients Understand Addiction. American Journal of Medicine, 2019, 132, 269-271.	0.6	6
78	Continuation of outpatient buprenorphine therapy after dispensing Buprenorphine-Naloxone from the emergency department. Clinical Toxicology, 2022, 60, 429-432.	0.8	6
79	Patients With Opioid Use Disorder Deserve Trained Providers. Annals of Internal Medicine, 2020, 172, 772-773.	2.0	5
80	Dismantling Buprenorphine Policy Can Provide More Comprehensive Addiction Treatment. NAM Perspectives, 2019, 2019, .	1.3	5
81	Opioid Use Disorder Diagnosis and Management. , 2022, 1, .		5
82	â€~Policies that Punish the Powerless' in a supplyâ€led illicit fentanyl market. Addiction, 2019, 114, 781-782.	1.7	4
83	Evaluating disparities in prescribing of naloxone after emergency department treatment of opioid overdose. Journal of Substance Abuse Treatment, 2022, 139, 108785.	1.5	4
84	Personal viewpoint on opioid agonist therapy and transplantation. American Journal of Transplantation, 2018, 18, 2869-2872.	2.6	3
85	Facing Addiction. Psychiatric Annals, 2019, 49, 47-54.	0.1	3
86	Performance Metrics of Substance Use Disorder Care Among Medicaid Enrollees in New York, New York. JAMA Health Forum, 2022, 3, e221771.	1.0	3
87	Case 6-2019: A 29-Year-Old Woman with Nausea, Vomiting, and Diarrhea. New England Journal of Medicine, 2019, 380, 772-779.	13.9	2
88	X-Waiver Exemption in the Treatment of Opioid Use Disorder—Reply. JAMA - Journal of the American Medical Association, 2021, 326, 442.	3.8	2
89	709. Multidisciplinary Drug Use Endocarditis Team (DUET): Results From an Academic Center Cohort. Open Forum Infectious Diseases, 2020, 7, S405-S407.	0.4	2
90	HIV among marginalized populations in Rhode Island. Medicine and Health, Rhode Island, 2009, 92, 244-6.	0.1	2

#	Article	IF	CITATIONS
91	Creation of a Multidisciplinary Drug Use Endocarditis Treatment (DUET) Team: Initial Patient Characteristics, Outcomes, and Future Directions. Open Forum Infectious Diseases, 2022, 9, ofac047.	0.4	2
92	Shifting Focus to Evidence-Based Management of Substance Use Disorders. Annals of Internal Medicine, 2022, , .	2.0	2
93	The Reply. Journal of Addiction Medicine, 2017, 11, 331-332.	1.4	1
94	Stigmatizing Language About Neonatal Abstinence Syndrome. JAMA - Journal of the American Medical Association, 2018, 320, 722.	3.8	1
95	IMPROVING MEASURES OF DYADIC OUTCOMES IN PERINATAL SUBSTANCE USE RESEARCH. Addiction, 2020, 115, 1787-1788.	1.7	1
96	Management of Opioid Agonist Treatment for Opioid use Disorder in the Setting of Solid Organ Transplant. Transplantation, 2021, Publish Ahead of Print, .	0.5	1
97	Prevalence of Cannabis Use and Cannabis Route of Administration among Massachusetts Adults in Buprenorphine Treatment for Opioid Use Disorder. Substance Use and Misuse, 2022, 57, 1104-1110.	0.7	1
98	Sitting With Sorrow. Academic Medicine, 2010, 85, 987.	0.8	0
99	The One Liner. Academic Medicine, 2011, 86, 1555.	0.8	0
100	Final Moments. Journal of General Internal Medicine, 2011, 26, 98-98.	1.3	0
101	Keep Coming. Journal of General Internal Medicine, 2013, 28, 330-330.	1.3	0
102	One Shot. Journal of General Internal Medicine, 2014, 29, 968-969.	1.3	0
103	The Reply. American Journal of Medicine, 2015, 128, e31.	0.6	0
104	Outcomes of Outpatient Antibiotic Treatment of Injection Drug Users Discharged to Home With Central Venous Access. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
105	The Reply. American Journal of Medicine, 2016, 129, e251.	0.6	0
106	The Reply. American Journal of Medicine, 2017, 130, e119.	0.6	0
107	Case 37-2017: A Man with Unintentional Opioid Overdose. New England Journal of Medicine, 2018, 378, 872-873.	13.9	0
108	De-Stigmatizing the Language of Addiction #429. Journal of Palliative Medicine, 2022, 25, 155-157.	0.6	0